Trump to Nominate Heidi Overton for FDA Commissioner
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Heidi Overton is expected to be nominated by President Trump for FDA commissioner, drawing on her role as deputy director of domestic policy at the White House
- Overton has led major health initiatives in Trump’s second term, including efforts to redesign the food pyramid and overhaul the childhood vaccine schedule
- Overton has worked closely with the Department of Health and Human Services and negotiated drug pricing deals with pharmaceutical companies
- Trump is set to appoint a White House insider to the FDA, bypassing traditional agency leadership pipelines in favor of a trusted policy adviser
- Overton has at times clashed with leaders of the Make America Healthy Again movement, signaling potential friction with populist health factions
Why it matters: Overton’s nomination would place a White House loyalist with direct policy experience—and political tensions—into the FDA’s top role, shifting the agency’s priorities toward administration-driven initiatives and potentially intensifying scrutiny over vaccine and drug pricing policies. The move bypasses career regulators, elevating political alignment over technical pedigree.
Ask SkimNews
